跳至主要内容
临床试验/NCT00328666
NCT00328666已完成不适用

Cardiovascular Effects of Iyengar Yoga vs. Enhanced Usual Care in Patients With High-normal to Stage I Hypertension

University of Pennsylvania2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2005年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
systolic blood pressure

研究概览

简要总结

The purpose of this study is to compare the effects of 12 weeks of structured classes of either iyengar yoga (IY) or an enhanced usual care intervention on blood pressure, heart rate variability, quality of life measures, lipid measures, and safety in patients with high-normal to stage I hypertension.

详细描述

This is a single site, parallel, non-blinded, randomized controlled trial to assess the safety and efficacy of 12 weeks of structured IY vs. enhanced usual care in adults with high-normal to stage I HTN. All potential subjects will be screened first by telephone and then by an outpatient visit at the General Clinical Research Center (GCRC) at either the hospital of the University of Pennsylvania (HUP) or the Presbyterian Medical Center (PMC). Eligible subjects will then make 4 visits to the GCRC where, during 3 visits, they will be admitted overnight to have non-invasive 24 hour recordings of blood pressure and heart rate variability as well as periodic blood and urine collections. In order to assess durability of biologic effects once the formal intervention is stopped, we added a 4 week follow up visit. The entire study duration is 18 weeks (16 weeks post-randomization) and includes a total of 5 visits. Subjects will be randomized to either the IYP or Blood Pressure Education Program (BPEP) which will be incorporated into off-site, small group classes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects must be willing to, and have the capacity for, giving written informed consent.
  • Between the ages of 18 and 70
  • Blood pressure (BP) criteria: systolic blood pressure (SBP) of > 130 but < 160 mm Hg and diastolic blood pressure (DBP) < 100 mmHg
  • All subjects must be willing to comply with all study-related procedures.

排除标准

  • Female subjects who are pregnant or post partum < 3 months
  • Subjects currently taking blood pressure lowering medications or dietary supplements (magnesium, potassium, calcium > 1200 mg/day, fish oils > 2000 mg/day, ephedra, hawthorn, forskolin)
  • Non-dominant arm circumference > 50 cm
  • Subjects with body mass index (BMI) >= 40.0 or < 18.5 kg/m2
  • Subjects who have practiced IY in the last 12 months or those who have practiced any form of yoga > 2 times (2x)/month in the previous 6 months.
  • Subjects who have received an experimental drug, used an experimental medical device within 30 days prior to screening, or who gave a blood donation of greater than or equal to one pint within 8 weeks prior to screening.
  • Subjects with diabetes mellitus
  • Subjects with established cardiovascular disease
  • Subjects with known arrhythmias such as atrial flutter or fibrillation or those with cardiac pacemakers
  • Current users (within the previous 30 days) of any tobacco products
  • History of renal insufficiency based on estimated glomerular filtration rate < 60 ml/min
  • Women who consume > 10 alcoholic drinks per week and men who consume > 15 drinks per week.
  • Subjects with known autonomic neuropathy (e.g: Shy-Drager, orthostatic hypotension)
  • Subjects with known secondary causes of hypertension (renal artery stenosis, pheochromocytoma, coarctation of aorta, hyperaldosteronemia)
  • Regular use of benzodiazepines, anti-psychotic drugs or corticosteroids (> 1x per month). Stable doses (3 months) of antidepressants (selective serotonin reuptake inhibitors [SSRIs] or tricyclic antidepressants [TCAs]) will be allowed.
  • Known severe musculoskeletal problems such as spinal stenosis that may limit participation in yoga
  • Subjects who actively practice (> 2x/month) other mind-body therapy (MBT) such as Qigong, Tai Chi, or meditation.

结局指标

主要结局

systolic blood pressure

次要结局

  • pulse wave velocity
  • safety markers
  • physiologic markers of stress
  • insulin resistance
  • heart rate variability
  • lipids
  • quality of life measures

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验